All In Biotech

Free tool

FAERS Monitor: Qfitlia

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219019 or its brand name (Qfitlia, Fitusiran Sodium). Reports on generic versions are filed under their own applications.

Reports

56

Serious

23

41% of reports

Hospitalization

13

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • haemorrhage17
  • arthralgia9
  • off label use8
  • contusion7
  • chest pain5
  • haemarthrosis5
  • condition aggravated4
  • pain4
  • pain in extremity4
  • compartment syndrome3
  • fall3
  • hepatic enzyme increased3
  • muscle haemorrhage3
  • peripheral swelling3
  • spontaneous haemorrhage3

Reports by year received

View as table
YearReports
20241
202512
202643

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,103 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
spontaneous haemorrhageSignal31101.5365.72,283
compartment syndromeSignal3432.5143.7895
muscle haemorrhageSignal3281.093.4580
haemarthrosisSignal5209.790.8840
haemorrhageSignal1761.141.1950
contusionSignal727.313.7153
hepatic enzyme increasedSignal316.55.530
chest painSignal510.14.433
arthralgiaSignal98.14.550
peripheral swellingSignal37.32.411
pain in extremitySignal45.12.010
condition aggravatedSignal44.91.99
off label useSignal83.41.812
fall33.41.13
pain42.41.02

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.